A genetically engineered drug known as BL22 has sent a type of cancer called hairy cell leukemia into full remission in 11 of 16 patients, a study shows.
The findings, reported in the July 26 NEW ENGLAND JOURNAL OF MEDICINE, suggest that BL22 may become a treatment for this type of leukemia.
The other three had their cancer recur within 16 months of being treated with BL22 but then were successfully treated again, Kreitman says.
The two proteins, BL22 and HA22, are recombinant immunotoxins that specifically target cancers derived from B-cells that express the CD22 antigen.
BL22 is currently in Phase II clinical studies for the treatment of hairy cell leukemia (HCL).
Chief, NCI's Laboratory of Molecular Biology, and to assume responsibility for continued development of BL22 (renamed GCR-3888) including overseeing clinical development, supplying material for clinical trials at the NCI, and registration and commercialization as appropriate.
Among these novel agents are: ABT-510, AP5280, BL22
, ZD6126, resmycin, Bay 43-9006, Bay 59-8862, karenitecin, BMS-214662, BMS-188797, BMS-275183, BMS-310705, DJ-927, DRF-1042, 131I-c81C6, LY317615, LY293111, rhAngiostatin, FK866, TNFerade, GF120918, GW572016, ILX23-7553, isocoumarin, BB-10901TAP, cantuzumab mertansine, Protaxel, TP-38, KOS-862, PaTrin-2, EMD 72000, heat-shock protein (HSP)-based vaccine, SS1[dsFv]-PE38, IL-13-PE38QQR, liposome-entrapped mitoxantrone (LEM), Pretarget Lymphoma, DCVax-prostate, PKI166, LAF389, HMN-214, TroVax, CP-547,632, CI-1040, AG2037, CP-471,358, Kahalalide F, Aplidin, anhydrovinblastine (AVLB), PX12, Gimatecan, SU6668, TAS-102, TZT-1027T607, ING-1 antibody, etc.